Induction outcome by Pgp expression and treatment arm
. | AraC-DNR (N = 59) . | AraC-DNR (N = 31) . | AraC-DNR + CsA (N = 70) . | AraC-DNR + CsA (N = 37) . | ||||
---|---|---|---|---|---|---|---|---|
No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | |
Pgp− (D < 0.20) patients only | ||||||||
CR | 20 | 34 (22-47) | 27 | 39 (27-51) | ||||
RD | 29 | 49 (36-63) | 25 | 36 (25-48) | ||||
Died during aplasia | 2 | 3 | 0 | 0 | ||||
Indeterminate5-150 | 6 | 10 | 12 | 17 | ||||
Not adequately assessed | 2 | 6 | 6 | 9 | ||||
Pgp+ (D ≥ 0.20) patients only | ||||||||
CR | 8 | 26 (12-45) | 17 | 46 (29-63) | ||||
RD | 14 | 45 (27-64) | 11 | 30 (16-47) | ||||
Died during aplasia | 1 | 3 | 2 | 5 | ||||
Indeterminate5-150 | 8 | 26 | 4 | 11 | ||||
Not adequately assessed | 0 | 0 | 3 | 8 |
. | AraC-DNR (N = 59) . | AraC-DNR (N = 31) . | AraC-DNR + CsA (N = 70) . | AraC-DNR + CsA (N = 37) . | ||||
---|---|---|---|---|---|---|---|---|
No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | |
Pgp− (D < 0.20) patients only | ||||||||
CR | 20 | 34 (22-47) | 27 | 39 (27-51) | ||||
RD | 29 | 49 (36-63) | 25 | 36 (25-48) | ||||
Died during aplasia | 2 | 3 | 0 | 0 | ||||
Indeterminate5-150 | 6 | 10 | 12 | 17 | ||||
Not adequately assessed | 2 | 6 | 6 | 9 | ||||
Pgp+ (D ≥ 0.20) patients only | ||||||||
CR | 8 | 26 (12-45) | 17 | 46 (29-63) | ||||
RD | 14 | 45 (27-64) | 11 | 30 (16-47) | ||||
Died during aplasia | 1 | 3 | 2 | 5 | ||||
Indeterminate5-150 | 8 | 26 | 4 | 11 | ||||
Not adequately assessed | 0 | 0 | 3 | 8 |
Died within 7 days after completing induction therapy; or died later with (1) no posttreatment marrow examination and (2) no posttreatment peripheral blood smear demonstrating leukemia.